The Effect of Weight Loss on Serum Mannose-Binding Lectin(MBL) Levels (WLMBL)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00854412|
Recruitment Status : Completed
First Posted : March 3, 2009
Last Update Posted : March 3, 2009
High levels of mannose-binding lectin (MBL), an activator of a part of the immune system called the complement system, have been associated with increased mortality and risk of early signs of kidney damage in patients with type 2 diabetes. The effect of weight loss and changes in insulin resistance on MBL levels have been poorly elucidated.
This study includes 36 nondiabetic obese subjects, who will receive a very low- calorie diet (VLCD) of 800 kcal/day for 8 weeks.
Fasting blood samples will be obtained at baseline and after 8 weeks of VLCD and concentrations of MBL, glucose and insulin will be measured. Insulin resistance is assessed using the HOMA-IR method.
|Condition or disease||Intervention/treatment||Phase|
|Obesity Weight Loss||Other: Weight loss||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||36 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||The Effect of Weight Loss on Serum Mannose-Binding Lectin (MBL) Levels|
|Study Start Date :||March 1995|
|Actual Primary Completion Date :||June 1995|
|Actual Study Completion Date :||June 1995|
Other: Weight loss